Skip to content
Colorectal Cancer Clinical Trials

Cleveland, Ohio

Colorectal cancer clinical trials in Cleveland, OH

36 colorectal cancer studies are recruiting participants at sites in Cleveland as of November 16, 2026, according to ClinicalTrials.gov. Colorectal Cancer Clinical Trials can help you understand your options and connect with a study team.

Call (888) 385-9581
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Cleveland at a glance

  • 36 studies are recruiting at a site in Cleveland.
  • By phase: Phase 1 (9), Phase 1/2 (11), Phase 2 (4), Phase 2/3 (1), Phase 3 (6), No phase (3), Observational (2). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (27), university, hospital or other (7), government (2).
  • Most recent update to one of these records: November 12, 2026.

Studies recruiting in Cleveland

Basic details from each study's public record (the 30 most recently updated of 36). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Verastem, Inc.
    Study site
    Case Western, University Hospitals Cleveland Medical Center
    Registry record
    NCT07659795 · updated
  2. Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Solstice Oncology, Inc.
    Registry record
    NCT07808151 · updated
  3. The Vanguard Study: Testing a New Way to Screen for Cancer

    • No phase
    • Ages 45 to 75
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Louis Stokes Cleveland VA Medical Center
    Registry record
    NCT06995898 · updated
  4. Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Summit Therapeutics
    Registry record
    NCT07228832 · updated
  5. Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps

    • No phase
    • Ages 45 to 70
    • All sexes
    Sponsor
    NRG Oncology
    Study sites
    Case Western Reserve University · Louis Stokes Cleveland VA Medical Center
    Registry record
    NCT05080673 · updated
  6. Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    NRG Oncology
    Study sites
    Cleveland Clinic Cancer Center/Fairview Hospital · Cleveland Clinic Foundation
    Registry record
    NCT05174169 · updated
  7. A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Bayer
    Study site
    Cleveland Clinic - Oncology Department
    Registry record
    NCT06760819 · updated
  8. Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    University Hospitals Cleveland Medical Center
    Registry record
    NCT07397338 · updated
  9. A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study sites
    Cleveland Clinic Cancer Center Fairview Hospital Moll Pavilion · Taussig Cancer Insititute Cleveland Clinic · University Hospitals Cleveland Medical Center
    Registry record
    NCT06662786 · updated
  10. A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Kumquat Biosciences Inc.
    Study site
    Cleveland Clinic, Taussig Cancer Institute
    Registry record
    NCT06720987 · updated
  11. A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    University Hospital of Cleveland
    Registry record
    NCT06750094 · updated
  12. A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Kumquat Biosciences Inc.
    Study site
    UH Cleveland Medical Center
    Registry record
    NCT07542704 · updated
  13. A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Genmab
    Study site
    Cleveland Clinic
    Registry record
    NCT03526835 · updated
  14. A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Astellas Pharma Inc
    Study site
    University Hospitals - UH Cleveland Medical Center
    Registry record
    NCT07094204 · updated
  15. Lead-212 PSV359 Therapy for Patients With Solid Tumors

    • Phase 1/2
    • Ages 18 to 90
    • All sexes
    Sponsor
    Perspective Therapeutics
    Study site
    Cleveland Clinic
    Registry record
    NCT06710756 · updated
  16. JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Jacobio Pharmaceuticals Co., Ltd.
    Study site
    Cleveland Clinic Foundation
    Registry record
    NCT06973564 · updated
  17. The Cancer of the Pancreas Screening-5 CAPS5)Study

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Johns Hopkins University
    Study site
    Case Comprehensive Cancer Center, Case Western Medical Reserve
    Registry record
    NCT02000089 · updated
  18. Testing for Safety and Colorectal Cancer Preventive Effects of ONC201

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Cleveland Clinic Foundation
    Registry record
    NCT05630794 · updated
  19. Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Institut de Recherches Internationales Servier
    Study site
    Cleveland Clinic
    Registry record
    NCT05786924 · updated
  20. Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study site
    University Hospitals Cleveland Medical Center
    Registry record
    NCT07222800 · updated
  21. FOG-001 in Locally Advanced or Metastatic Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Parabilis Medicines, Inc.
    Study sites
    Cleveland Clinic · University Hospitals Cleveland Medical Center, Seidman Cancer Center
    Registry record
    NCT05919264 · updated
  22. Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Bicara Therapeutics
    Study site
    Cleveland Clinic
    Registry record
    NCT04429542 · updated
  23. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    • Phase 1/2
    • Ages 12 and older
    • All sexes
    Sponsor
    PMV Pharmaceuticals, Inc
    Study site
    The Cleveland Clinic Taussig Cancer Center
    Registry record
    NCT04585750 · updated
  24. Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Exelixis
    Study site
    Exelixis Clinical Site #10
    Registry record
    NCT05176483 · updated
  25. EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    Case Comprehensive Cancer Center
    Study site
    University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center
    Registry record
    NCT06263088 · updated
  26. A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    EvolveImmune United, Inc
    Study site
    University Hospitals Cleveland Medical Center
    Registry record
    NCT07217171 · updated
  27. ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    Guardant Health, Inc.
    Study site
    Cleveland Clinic
    Registry record
    NCT05059444 · updated
  28. Safety of HRX215 in Patients After Minor and Major Liver Resection

    • Phase 1/2
    • Ages 18 to 75
    • All sexes
    Sponsor
    HepaRegeniX GmbH
    Study site
    Cleveland Clinic
    Registry record
    NCT06638502 · updated
  29. A Phase 1/1b Study of IAM1363 in HER2 Cancers

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Iambic Therapeutics, Inc
    Study sites
    Cleveland Clinic · University Hospital Cleveland Medical Center
    Registry record
    NCT06253871 · updated
  30. ctHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Locally-Advanced Anal Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Jennifer Dorth
    Study site
    Case Comprehensive Cancer Center, Cleveland Clinic Taussig Cancer Center
    Registry record
    NCT07425054 · updated

Source: ClinicalTrials.gov. Data processed . See every colorectal cancer study recruiting in Cleveland, OH on ClinicalTrials.gov.

Ask about studies near Cleveland

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Ohio

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Colorectal Cancer Clinical Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 385-9581

or send a short form

How should we reach you?

Call